Grape King Bio Ltd. announced that it applied to FDA for A Phase II Clinical Trial Review in Humans for GKAC. Cause of occurrence: GKAC, a new botanical drug under development by the Company,02/11 has applied to the US Food and Drug Administration (USFDA) for a Phase II clinical trial review (IND number: 160609) for non-alcoholic steatohepatitis in humans. Name or code name of new drug research and development: GKAC.

The current research and development stage: Submit application/approved/not approved/results of each phase of human clinical trials (including interim analysis): Submit application; risks faced by the company and countermeasures for those without permission from the competent authority of the target business: Not applicable; those who have been approved by the competent authority of the target business, future business direction: Not applicable; and the accumulated R&D expenses that have been invested: As it involves information on future international licensing negotiations and in order to avoid affecting the licensing amount and protect the rights and interests of investors, for the time being expenses will not be disclosed.